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Dendritic cells (DCs) are highly specialized antigen presenting cells of the immune system which play a key role in regulating
immune responses. Depending on the method of antigen delivery, DCs stimulate immune responses or induce tolerance. As a
consequence of the dual function of DCs, DCs are studied in the context of immunotherapy for both cancer and autoimmune
diseases. In vaccine development, a major aim is to induce strong, specific T-cell responses.This is achieved by targeting antigen to
cell surface molecules on DCs that efficiently channel the antigen into endocytic compartments for loading onto MHC molecules
and stimulation of T-cell responses.Themost attractive cell surface receptors, expressed on DCs used as targets for antigen delivery
for cancer and other diseases, are discussed.
1. Introduction
The most successful vaccines used to combat infectious dis-
ease are the live or live attenuated organisms as used in polio
and small pox vaccines. However, with purified proteins or
peptides, in most cases adjuvants or suitable danger signals
are necessary in order to prime T-cell responses. In the last
decade, dendritic cells (DCs), powerful antigen presenting
cells, have surfaced as the most important cells, to target an-
tigens for uptake, processing, and presentation to T cells [1].
DCs link the innate immune response to the adaptive im-
mune response in that they bind pathogens and are able to
stimulate T-cell responses against antigens. Targeting anti-
gens to DC is therefore an appropriate method to stimulate
effective immune responses. Targeting cell surface receptors
on DCs represents a more direct and less laborious method
and has been the subject of considerable recent investigation.
Numerous receptors have been identified to be expressed
on DCs, including mannose receptor (MR), DC-SIGN,
scavenger receptor (SR), DEC-205, and toll-like receptors.
Targeting of these receptors is becoming an efficient strategy
of delivering antigens in DC-based anticancer immunother-
apy. Furthermore, pattern recognition receptors (PRRs) are
expressed by cells of the innate immune system which
bind to pathogen associated molecular patterns (PAMPs)
on pathogens. PRRs are also known as pathogen recog-
nition receptors or primitive pattern recognition receptors
as they evolved before other parts of the immune system,
mainly before adaptive immunity. PAMPs bind mannose,
lipopolysaccharide, fucose, peptidoglycans, lipoproteins and
glucans. PRRs are classified into 2 groups: (i) endocytic PRRs,
which phagocytose microorganisms, bind to carbohydrates,
and include themannose receptor (MR), glucan receptor, and
scavenger receptor, and (ii) signaling PRRs which include
the membrane bound toll-like receptors (TLR) and the cyto-
plasmicNOD-like receptors.Themembrane bound receptors
fall into 3 categories: (i) receptor kinases, (ii) TLR, and (iii)
C-type lectin receptors. Targeting of these receptors is
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Figure 1: Schematic representation of dendritic cells expressing a number of different cell surface receptors which are targets for antigen
targeting therapies.
becoming an efficient strategy of delivering antigens in DC-
based anticancer immunotherapy.
2. C-Type Lectin Receptors
Calcium-dependent (C-type) lectins consist of a large family
of lectins which consist of carbohydrate recognition domains.
TheC-type lectin family includes themannose receptor,man-
nose binding lectin, and ficolins and are active in immune-
system functions such as pathogen recognition. In addition,
dendritic cell C-type lectins, DC-SIGN, DC-SIGNR, DCAR,
DCIR, Dectins, and DLEC are important in dendritic cell
trafficking, formation of the immunological synapse, and
inducing cellular and humoral immunity, bringing together
both adaptive and innate immunity (Figure 1).
2.1. Group 1 C-Type Lectin Receptors: The Mannose Receptors
2.1.1. Mannose Receptor. The mannose receptor (MR,
CD206) is a C-type membrane lectin, carbohydrate (man-
nose, fucose, glucose, maltose, and GlcNAc) binding protein
expressed by DCs and macrophages (Table 1 and Figure 1).
MR binds to carbohydrates present on the cell walls of
yeast, viruses, and bacteria, leading to endocytosis and
phagocytosis [2]. Interestingly, human immunodeficiency
virus (HIV) gp120 binds to MR on vaginal epithelial cells
and induces the production of matrix metalloproteinases,
facilitating transport ofHIVacross the vaginal epithelium [3].
In addition, HIV binds to the mannose receptor in sperm
cells, suggesting that sperm cell-HIV interaction is an
important source of infection [4]. The MR is part of the
multilectin receptor family and provides a link between
innate and adaptive immunity [5]. There are two types of
MR in humans each encoded by its own gene, (i) mannose
receptor C type 1 (MRC1) and (ii) mannose receptor C type
2 (MRC2).
TheMR has been used as a target for vaccines, where DCs
take up mannosylated proteins and utilize peptide epitopes
for antigen presentation. The high expression of MR on DCs
and macrophages suggests that the MR plays a key role in
antigen recognition [6, 7]. The uptake of antigens by the MR
allows processing and presentation via the MHC class I and
II pathways [8–10], hence, suggesting MR a viable target for
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Table 1: Summary of dendritic cell receptors targeted for vaccine development: C-type lectin receptors.
Receptor Designation Function
1. Group 1 C-type lectin receptors
1.1. Mannose receptor CD206
Expressed on macrophages and DCs. Binds to mannan, mannose,
fucose, glucose, maltose, GlcNAc, lipoarabinomannan, cell wall of yeast,
viruses, and bacteria leading to phagocytosis/endocytosis. Used to target
protein, peptides, DNA, dendrimers, liposomes, and anti-MR antibodies
for vaccine development with Th1, Th2, CTL, and Ab responses induced.
Targeting antigens to MR using mannan has been used in human
clinical trials.
2. Group 2 C-type lectin receptors
2.1. Dendritic cell-specific intercellular
adhesion molecule-3-grabbing
nonintegrin (DC-SIGN)
CD209
Clec4L
Expressed on immature DCs, macrophages endothelial vascular cells,
atherosclerotic plaques, and lymphatic vessels, not on placmacytoid
DCs. Binds to mannan, mannose, fucose, GlcNAc, GalNAc, yeast, lewis
blood group antigens Lex, HIV-1 gp120, ebola virus, hepatitis C virus,
dengue virus, respiratory syncytial virus, measles virus,Mycobacterium
tuberculosis, Leishmania amastigote, Helicobacter pylori, Leishmania
mexicana, Schistosoma mansoni, Porphyromonas gingivalis, Neisseria
gonorrhoeae, Candida albicans, house dust mite (Der p1), and dog
allergens (Can f1). Interacts with ICAM-3 and ICAM-2. Targeting
DC-SIGN using antigen linked to anti-DC-SIGN antibodies,
Manalpha-6 Man, lactoside, and Lewis oligosaccharide, stimulates T-cell
and/or antibody responses, and has been studied as a potential receptor
for vaccine targeting. Eight murine homologues identified, SIGN-R1
(CD209b) to SIGN-R8.
2.1.1. L-SIGN or DC-SIGNR
CD299
CD209L
Clec4M
Expressed on liver sinusoidal cells, lymph nodes, and endothelial
vascular cells, but not on DCs. Binds to HIV gp120, Man9GlcNAc2, HIV,
simian immunodeficiency virus, ebola virus, hepatitis C virus, and
respiratory syncytial virus. Targeting L-SIGN with anti-L-SIGN
antibodies induces T-cell responses. Targeting L-SIGN shows promise
for the development of targeted vaccines.
2.1.2. Liver and lymph node sinusoidal
cell type lectin (LSECtin) Clec4G
Expressed in liver, lymph nodes, sinusoidal endothelial cells, DCs, and
Kupffer cells. Binds to N-acetyl-glucosamine, fucose, ebola virus,
filovirus glycoproteins, lymphocytic choriomeningitis virus, S-protein of
SARS coronavirus, and to CD44, but not to mannose, HIV, and hepatitis
C. Coexpressed with DC-SIGNR and CD23. Antibody or
ligand-mediated engagement of LSECtin activates rapid internalization,
indicating that LSECtin may be a suitable receptor for targeting antiges
in the development of vaccination regimes.
2.1.3. C-type lectin immune receptor
(CIRE)
(murine homologue of DC-SIGN)
CD209
Expressed by immature CD8− splenic DCs (CD8−CD4+ and
CD8−CD4−), on some CD4+ DCs, plasmacytoid pre-DCs, and not by,
CD8+ DCs, macrophages, or monocytes. It is a ligand for ICAM-3 and
binds to HIV. Polyanhydride nanoparticles covalently linked to
dimannose and lactose matures DCs and are internalized by DCs. CIRE
shows promise as an appropriate target for antigen delivery for improved
vaccine development.
2.2. Langerin CD207Clec4K
Expressed on Langerhans cells, CD103+ DCs, and splenic CD8+ DCs.
Binds to mannose and internalizes mannose residues into Birbeck
granules, where Langerin is expressed. Anti-Langerin antibody targeting
antigens to Langerin is endocytozed in vitro and in vivo and induces Th1
and antibody responses.
2.3. MGL
(human macrophage galactose- and
N-acetylgalactosamine-specific C-type
lectin)
Expressed on macrophages, immature DCs galactose, GalNAc, Tn
antigen, filoviruses, and gonorrhea. GalNAc modified peptides to target
MGL receptor expressed on murine and human DCs, which stimulates
T-cell and antibody responses, and this approach could be used to
design novel anticancer vaccines.
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Table 1: Continued.
Receptor Designation Function
2.4. Dectin-1 or beta-glucan receptor
(DC-associated C-type lectin-1)
DCAL-1
Clec7A
Expressed on myeloid DCs, CD8−CD8− DCs, dermal DCs, monocytes,
macrophages, neutrophils, T cells, B cells, mast cells, eosinophils, and
monocytes. Binds to beta-glucan on yeast, mycobacteria, plant cell walls,
Saccharomyces, Candida, Pneumocystis, Coccidioides, Penicillium, and
Aspergillus, but not Cryptococcus fungal species, and interacts with
CD37. Anti-Dectin-1 and anti-Dectin-2 antibodies linked to proteins
stimulate CD8+ and CD4+ T cells, and immunization with beta-glycan
modified proteins induces CD4+ andTh17 bias responses.
2.4.1. DNGR-1
(NK lectin group receptor-1) Clec9A
Expressed on murine CD8+ DCs not on CD4+ DCs, on CD11c+ DCs
but not by CD11c− cells (B cells, T cells, NK cells, NKT cells,
macrophages, and granulocytes), on plasmacytoid DCs, and on human
blood DCsBDCA-3+ DCs) and monocytes (CD14+CD16−). Highly
expressed on Flt3 ligand bone marrow derived CD8+ DCs. Target for
immune response induction.
2.4.2. Myeloid inhibitory C-type lectin
receptor (MICL) Clec12A
Homologous to Dectin-1 and part of Dectin-1 cluster. Also termed as
CLL-1, DCAL-2, and KLRL1. Expressed on granulocytes, monocytes,
macrophages, B cells, CD8+ T cells in peripheral blood, and DCs.
2.4.3. C-type lectin-like receptor 2
(CLEC2) Clec1B
Expressed on NK cells, monocytes, granulocytes, platelets,
megakaryocytes, and liver sinusoidal epithelial cells. Binds to HIV-1 and
facilitates HIV-1 spread to other cells and binds to snake venom
rhodocytin. Not much is known regarding stimulating immune
responses; however, colocalization with DC-SIGN suggests that it may
have an immune stimulatory effect.
2.4.4. CLEC12B
(macrophage antigen H) Clec21B
Part of the NK gene complex/dectin-1 cluster of C-type lectin receptors.
Expressed on macrophages, monocytes, and DCs. Not much is known
regarding its function.
2.4.5. LOX-1
(Lectin-like receptor for oxidized density
lipoprotein-1)
Clec8A
Part of the dectin-1 cluster of C-type lectin receptors and scavenger
receptor family. Expressed on endothelial cells, smooth muscle cells,
platelets, fibroblasts, and macrophages. Binds to Gram-positive and
Gram-negative bacteria, oxidized LDL modified lipoproteins,
phospholipids, apoptotic cells, C-reactive protein, and heat shock
protein (HSP)-70. Targeting LOX-1 induces immune responses and is a
promising target for cancer immunotherapy.
2.5. DC immunoreceptor subfamily
2.5.1. DC immunoreceptor (DCIR) Clec4A
Expressed on plasmacytoid DCs, immature and mature
monocyte-derived DCs monocytes, macrophages, and B cells. Binds to
TLR9. Targeting DCIR stimulates immune responses especially CD8+ T
cells.
2.5.2. Dectin-2
(or beta-glucan receptor)
DCAL-2
Clec6A
Expressed on DCs, macrophages neutrophils, and monocytes. Binds to
beta1,3 and beta1,6-linked glucans on yeast, mycobacteria, and plant cell
walls. Targeting dectin-2 stimulates immune responses in mice.
2.5.3. Blood DC antigen (BDCA-2) Clec4C Expressed on human blood DCs. Targeting BDCA-2 suppressesIFN-alpha/beta cytokine secretion.
antigen delivery for vaccine development. Indeed, mannosy-
lated peptides and proteins stimulate MHC class II specific
T cells with 200 to 10,000-fold higher efficiency compared
to peptides or proteins that are not mannosylated [10].
There is a 100-fold enhanced presentation of soluble antigens
to T cells after being internalized by the MR on DCs, as
compared to antigens internalized via fluid phase [9].
The MUC1 antigen conjugated to oxidized mannan (poly-
mannose, comprising aldehydes) leads to rapid and 1,000
timesmore efficientMHCclass I presentation toCD8+T cells
with a preferential T1 response, compared to MUC1 antigen
conjugated to reduced mannan (no aldehydes) [8]. MUC1
antigen conjugated to reduced mannan results in class II
presentation and a T2 immune response [8]. Both conjugate
formulations, oxidized and reduced mannan, bind equally to
the MR and are taken up into early endosomes [8]. MUC1-
oxidized mannan rapidly escapes from the early endosomes
into the cytosol for proteasomal processing and transport to
the endoplasmic reticulum,Golgi apparatus, andMHCclass I
on the cell surface. By contrast, MUC1-reduced mannan
remains in the early endosomes, to late endosomes, and to
lysosomes, resulting inMHCclass II presentation of antigens.
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Furthermore, both oxidized and reduced mannan stimulated
bone marrow derived DCs, showed enhanced allogeneic T-
cell proliferation, and enhanced OTI/OTII peptide specific
T-cell responses in vitro. Mice injected with oxidized or
reduced mannan induced a mature phenotype of lymph
node and splenic DCs [11]. Oxidized and reduced mannan
both stimulated upregulation of inflammatory cytokines
interleukin-(IL-) 1beta and tumour necrosis factor-alpha;
however, oxidizedmannan stimulated IFN-gamma, IL-12p40
cytokines whereas reduced mannan stimulated IL-4, IL-10,
and IL-13 [11]. Moreover, the activation of DCs was toll-like
receptor-4 (TLR-4) dependent [11]. Thus, the mode of man-
nan conjugation to antigen is important as the differential
immune responses result [12–18]. These studies provided the
first demonstration that the MR aided antigens into both
the MHC class I or II pathways depending on the chemical
modification of mannan. In addition, ex vivo targeting of
macrophages or DCs with oxidized mannan-MUC1 and
reinjection intomice, induces strong CTL responses and pro-
tects against MUC1 tumor challenge [6, 19–21]. Humans are
injected with oxidized mannan-MUC1 which induce cellular
and humoral immune responses and protect against recur-
rence in breast cancer patients [21–24]. Ex vivo culture of
human DC and pulsing with oxidized mannan-MUC1 and
reinjection into patients with adenocarcinoma result in
strong cellular immune responses and clinical responses [25].
Moreover, reduced mannan conjugated to myelin basic pro-
tein (MBP) 87–99 or 83–99 altered peptide ligands [26–
28] (R91A96MBP
87−99
, A91A96MBP
87−99
, and Y91MBP
83−99
)
divert Th1 IFN-gamma responses to Th2 IL-4 responses
[29, 30]. Likewise, reduced mannan conjugated to cyclic
A91A96MBP
87−99
and A91MBP
83−99
peptides significantly
altered predominant Th1 responses to predominant Th2
responses [31–33]. Thus, mannan in its oxidized form has
been shown to be effective as an anticancer vaccine, and
mannan in its reduced form shows promise as a vaccine
against autoimmune diseases such as multiple sclerosis.
DNA immunization is an attractive form of vaccination,
which has shown promising results only in small animal
models. Targeting the MR for DNA vaccines is a viable ap-
proach for the rational design of DNA vaccine strategies [34].
Mannosylated liposomes incorporating OVA DNA induced
strong CTL responses in mice as compared to nonmannosy-
lated complexes [35]. Complexation of oxidized or reduced
mannan to OVA DNA via poly-l-lysine were able to stim-
ulate strong cellular and humoral immune responses in
mice [36, 37]. Using MUC1 DNA complexed to oxidized or
reduced mannan was more immunogenic (T-cell responses,
IFN-gamma secretion, low dose administration, and tumor
protection) compared to MUC1 DNA alone [38]. In another
approach, cationic amphiphiles containing mannose mimics,
quinic acid, and shikimic acid headgroups are able to target
the MR on DCs, leading to effective immune responses and
tumor protection [39], suggesting that mannosylated DNA is
an effective approach in generating immune responses.
Dendrimers are repetitive branched molecules which
adopt a spherical 3-dimensional morphology. Dendrimers
have 3 major parts, a core, an inner shell, and an outer shell,
and attachment of compounds could be added in an attempt
to develop novel immunotherapeutics. Mannosylated den-
drimer OVA was shown to be taken up, processed, and
presented by bonemarrow derived DCs and Flt3-L DCs [40].
Mannosylated dendrimer OVA stimulated CD4+ and CD8+
T-cell responses and antibodies and protected mice against
a OVA+ tumor challenge. Mannosylated dendrimer OVA
induced DC maturation which was largely dependent on
TLR-4 [41].
Mannan coated cationic liposomes (nanoparticles) incor-
porating HIV-1 DNA stimulate cytotoxic T lymphocytes
(CTL), IFN-gamma, IgG2a, IgA, and delayed-type hypersen-
sitivity responses [42]. The binding and uptake properties of
mannan coated nanoparticles were 50% higher compared to
the nonmannan coated nanoparticles, byMR+ cell line, J774E
[43]. The binding and uptake were inhibited in the presence
of free mannan, suggesting that the uptake was receptor
dependent [43]. Anionic liposomes on the other hand, with
the bilayer composition of phosphatidylcholine, cholesterol,
phosphatidylglycerol, and phosphatidylserine do not bind
to DCs. However, mannosylation of anionic liposomes in-
creased their interaction to murine and human DCs, which
could be blocked with free mannan [44]. Thus, the type of
liposome is important in the development of effective vac-
cines, although mannan coating could overcome the pitfalls.
Mannosylated liposomes incorporating ErbB2 CTL and T
helper peptides and synthetic TLR2/1 or TLR2/6 agonists
induced higher therapeutic efficacy compared to nonmanno-
sylated liposomes [45]. In addition, mannosylated liposomes
bind and are endocytozed by immature DCs; however, only
nonspecific endocytosis is observed with nonmannosylated
liposomes [46]. Liposomes conatining multibranched man-
nosylated lipids bind with higher affinity to the MR leading
to effective uptake and endocytosis, compared to liposomes
containing the monomannosylated analogs [46]. Further-
more, mannan coated poly(D, L-lactide-co-glycolic acid) and
PLGA nanoparticles and enhanced CD4+ and CD8+ T-cell
responses compared to nonmannan coated nanoparticles
[47].
In addition, HER2 protein complexed to cholesteryl
group-bearingmannan or pullulan polysaccharides generates
CD8+ CTLs which reject HER2+ tumors in mice [48]. Fur-
thermore, mannosylated chitosan microspheres (MCMs)
incorporating Bordetella bronchiseptica antigen bound to the
MR on murine macrophages (RAW264.7 cells) in vitro and
induced strong IgA antibody responses in vivo [49]. However,
mannose coated stealth microspheres, although bound to the
MR, were not able to mature DCs in vitro [50].
Four lipid-core peptides were synthesized containing a
sequence from the human papillomavirus type-16 (HPV-16)
E7 protein (E744-62) and d-mannose. Immunization of mice
with d-mannose-E7 peptide reduced or cleared tumors more
effectively 37/40 compared to 21/30 in mice immunized
with nonmannosylated peptides [51]. Numerous vaccines use
keyhole limpet hemocyanin (KLH), to aid in antibody and T-
cell responses. KLH activates and matures DCs by upregulat-
ing CD40, CD80, CD83, CD86, andMHC class II cell surface
molecules and stimulating IL-12 and IL-10 cytokines [52].
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The interaction of KLH to DCs was noted to be partially
mediated by binding to the MR.
Cluster differentiation 1 (CD1) proteins, in particular,
CD1b expressed onmacrophages and DCs, present lipid anti-
gens (including lipid mycolic acid and lipoarabinomannan)
to T cells [53, 54]. The antigen presentation pathway for li-
poarabinomannan has been characterized, and the MR is
clearly responsible for uptake [55]. Lipoarabinomannan is en-
docytozed into early endosomes via the MR and from
late endosomes is loaded onto CD1b molecules for T-cell
presentation [55]. This study linked the MR to presentation
of glycolipids via CD1 and suggests that theMR plays a major
functional role in processing of carbohydrate antigens.
The melanoma associated antigen pmel17 fused to the
heavy chain of an anti-MR antibody (B11-pmel17) and pulsed
to DCs results in both MHC class I and class II presenta-
tion and CTL generation [56]. Likewise, human chorionic
gonadotropin beta protein expressed by cancer cells, coupled
to anti-MR antibody (B11-hCGbeta) generated MHC class I
and class II T-cell responses and lysed hCGbeta+ cell
lines [57]. T helper cells and CTL from cancer patients and
healthy subjects were effectively primed with B11-hCGbeta
pulsed DCs when a combination of TLR-ligands was used.
It was evident that when TLR3 (poly I:C ligand) or TLR7/8
(resiquimod ligand, R-848) were used, concomitant signaling
of DCs led to efficient antigen presentation by MR tar-
geting [58]. Thus, MR and TLR together both contribute
towards maturation and activation of DCs; in human clinical
trials this was well tolerated with strong immune responses
in cancer patients, and a phase II study is currently in
progress [59, 60]. Similarly, NY-ESO-1, a cancer-testis Ag
widely used in clinical cancer vaccine trials, was fused with
either anti-MR or anti-DEC205 antibodies [61]. NY-ESO-1-
antiMR antibody bound to the MR on DCs and NY-ESO-1-
anti-DEC-205 on DCs, leading to stimulation of CD4+ and
CD8+ T cells from peripheral blood mononuclear cells of
cancer patients [61]. In contrast, nonantibody targeted NY-
ESO-1 proteins only activated CD4+ T cells. Thus, targeting
either the MR or DEC205 on DCs is a promising vaccination
strategy to induce strong cellular immune responses.
In order to retain the characteristics of mannose rich car-
bohydrates and target the MR on DCs, antigens were ex-
pressed in yeast. Several recombinant ovalbumin (OVA) pro-
teins were generated in Pichia Pastoris which naturally man-
nosylated OVA [62]. Mannosylated OVA induced enhanced
antigen-specific CD4+ T-cell proliferation compared to non-
mannosylated OVA, and, uptake was primarily due to
mannose-specific C-type lectin receptors (MR and DC-
SIGN) [63]. Further, stronger CTL responses and IFN-
gamma, IL-2, IL-4, IL-5 cytokines were induced after vac-
cination in mice [64]. These studies demonstrate that yeast
derived mannosylation of antigens enhances immunogenic-
ity.Therapeutic strategies using tumor-specific immunoglob-
ulin (idiotype, Id) for lymphomas are promising. Id proteins
are usually produced via tumor-myeloma hybridomas or
recombinantmethods inmammalian, bacteria, or insect cells.
Using insect cells, the Id produced contain mannose residues
which have enhanced immunostimulatory properties (acti-
vation of DCs, CD8+ T-cell stimulation, and eradication of
lymphomas), compared to Id proteins made in mammalian
cells [65]. However, anti-lymphoma antibodies generated by
Id insect cell compared to mammalian cells were similar.
Thus, insect derived antigens are far more immunostimu-
latory compared to mammalian derived antigens, primarily
due to the expression of mannose which binds to the MR.
Humans with suppressed T cells have high prevalence
ofCryptococcosis. Soluble Cryptococcus neoformansmanno-
proteins (MP) are promising vaccine candidates due to their
ability to induces delayed-type hypersensitivity and Th1
cytokines. MP binds to the MR and results in CD4+ T-cell
stimulation and induce protective responses against C. neo-
formans and Candida albicans. The uptake of MP by DCs can
be inhibited either by competitive blockade of the MR or by
removal of carbohydrate residues critical for recognition [66].
Further,MPs increased the expression ofCD40,CD83,CD86,
MHC class I and II cell surface moleules, and IL-12 leading to
the maturation and activation of DCs [67]. It was clear that
the mannose groups on MP provided the immunogenicity
of cryptococcal MP and this finding supports vaccination
strategies that target the MR.
It is clear that antigen mannosylation is an effective
approach to potentiate antigen immunogenicity, due to the
enhanced antigen uptake and presentation by DCs and
macrophages.
2.2. Group 2 C-Type Lectin Receptors: Asialoglycoprotein
Receptor Family
2.2.1. DC-SIGN. Dendritic cell-specific intercellular adhe-
sion molecule-3-grabbing nonintegrin, (DC-SIGN ) also
known as CD209, Clec4L, is a C-type membrane lectins
abundantly expressed on immature DCs, macrophages,
endothelial vascular cells, atherosclerotic plaques, and lym-
phatic vessels, but not on plasmacytoid DCs (Table 1 and
Figure 1). Like the MR, DC-SIGN recognizes carbohydrates
including mannose, fucose, N-acetylgalactosamine, and N-
acetylgiucosamine residues on pathogens mediating endo-
cytosis, thus activating and tailoring the adaptive immune
response against pathogens. DC-SIGN also binds yeast
derived mannan and Lewis blood group antigens and sia-
lylation or sulfation of Lex completely abrogated binding to
DC-SIGN [68]. DC-SIGN contributes to HIV pathogenesis.
HIV-1 gp120, binds to DC-SIGN on monocyte derived
DCs more than 80% with residual binding to CD4, as
opposed to HIV-1 only binding to CD4 on blood DCs [69].
After binding to DC-SIGN on DCs, HIV-1 is transported
by DCs into lymphoid tissues and consequently facilitates
HIV-1 infection of target CD4+ T cells [70, 71]. DC-SIGN
also has high affinity binding for ebola virus, hepatitis
C virus, dengue virus, respiratory syncytial virus, measles
virus, Mycobacterium tuberculosis, Leishmania amastigote,
Helicobacter pylori, Leishmania mexicana, Schistosoma man-
soni, Porphyromonas gingivalis, Neisseria gonorrhoeae, and
Candida albicans, transmitting infection (virus, bacteria, and
yeast) to susceptible cells and, inducing Th1 Th2 T cell
responses [72–77]. Recently, it was shown that DC-SIGN
is the receptor for the major house dust mite (Der p1)
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and dog allergens (Can f1) [78]. There is no binding of DC-
SIGN with E. coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, and Staphylococcus aureus [68]. DC-SIGN was
identified through its high affinity interaction with ICAM-3
which facilitates DC interactions with T cells and contributes
to the regulation of primary immune responses [70, 71]. DC-
SIGN also interacts with ICAM-2 which is responsible for
DC migration [79]. In view of these findings, DC-SIGN has
implications for antigen targeting and stimulation of T-cell
responses and has been studied as a potential receptor for
vaccine targeting.
In order to understand the molecular basis of internal-
ization of ligands by DC-SIGN, the putative internalization
motif within the cytoplasmic tail was modified resulting
in reduced internalization after exposure to antigen [80].
DC-SIGN ligand complexes are internalized by DCs into
late endosomes, early lysosomes, and are processed and
presented to CD4+ T cells [80]. Further, anti-DC-SIGN
monoclonal antibodies are internalized up to 1,000-foldmore
efficiently compared to control monoclonal antibody and
found in intracellular vesicles, indicating that targeting DC-
SIGN targets the MHC class II pathway [81]. Anti-DC-SIGN
monoclonal antibody conjugated to KLH was rapidly inter-
nalized into the lysosomal compartment of DCs and induced
up to 100-fold increase stimulation of T cells compared to
KLH alone pulsedDCs [82]. In addition, anti-DC-SIGN anti-
body-KLH-targeted DCs induced proliferation of naive T
cells which recognized KLH T-cell epitopes presented by
MHC class I and II molecules [82] and inhibited tumor cell
growth in mice [83]. These studies use an anti-DC-SIGN
monoclonal antibody that binds to the carbohydrate recog-
nition domain. Recently, an anti-DC-SIGNmonoclonal anti-
body which binds to the neck region of DC-SIGNwas rapidly
internalized into early endosomes by DCs by a clathrin-
independent mechanism, unlike anti-DC-SIGN antibodies
which target the carbohydrate recognition domain are
internalized into late endosomes, via a clathrin dependent
mechanism [84]. Further, enhanced (up to 1,000-fold) T-
cell stimulation resulted using the antineck region DEC205
antibody [84]. Hence, targeting different regions of DEC205
results in distinct internalization modes, and shows potential
for targeted vaccination strategies.
Hamster bone marrow derived DCs, expressing high
levels of DEC205 and DC-SIGN, pulsed with tumor lysates
of hamster pancreatic cells and injected into tumor bearing
hamsters reduced tumor growth significantly [85], further
demonstrating that targeting DC-SIGN or DEC205 receptors
may be useful for the development of effective vaccines. Lipo-
somes containing calcein are rapidly taken up by immature
and mature myeloid DCs [86], and nanoparticles but not
microparticles deliver antigen to human DCs via DC-SIGN
in vitro [87], further demonstrating DC-SIGN as a targeted
receptor for vaccine design.
The melanoma antigen, Melan-A/Mart-1 (peptide 16–
40, containing the CD8+ HLA-A2 restricted T-cell epitope,
amino acids 26–35), was coupled to either Manalpha-6 Man
or lactoside, or a Lewis oligosaccharide [88]. The glycocon-
jugates containing Lewis oligosaccaride bound with high af-
finity to DC-SIGN were taken up by DCs into acidic vesicles
and presented by MHC class I and stimulated CD8+ T-cell
responses [88]. However, glycoconjugates containing lacto-
sidewere not taken up byDCs.Modification of themelanoma
antigen, gp100, with glycans (high mannose) interacted
specifically with DCs and induced enhanced CD4+ T-cell
responses [89]. Further, Lex oligosaccharides conjugated to
OVA targeted DC-SIGN on DCs effectively and stimulated
CTL and IFN-gamma secretion (but not IL-10) by T cells and
required 300-fold lower dose to immunize compared to OVA
immunization alone [90]. Using humanDC-SIGN transgenic
DCs, Lex-OVA was efficiently endocytozed and enhanced
OT-I CD8+ and OT-II CD4+ T-cell stimulation resulted,
compared to OVA alone [91]. The heparanase tumor antigen
is not able to elicit an immune response; however, conjugation
of heparanase to Lex was able to stimulate IFN-gamma cy-
tokine secretion by T cells, CTL responses and delay the
growth of established tumors in mice [92]. Liposomes mod-
ified to express Lex and LeB increased binding and inter-
nalization by human DCs which was further enhanced, up
to 100-fold, and stimulated both CD4+ and CD8+ T-cell
responses, in the presence of lipopolysaccharide, compared
to nonmodified liposomes. In addition, modified liposome-
LexLeB encapsulating the melanoma antigen MART-1 in the
presence of lipopolysaccharide also enhanced CD8+ T-cell
clone activation in vitro [93]. Polyamidoamine dendrimers
comprising LeB antigen are taken into lysosomes, and den-
drimers containing at least 16–32 glycan units are necessary
for antigen presentation and cytokine production [94]. Thus,
complexes using Le oligosaccharides to target DC-SIGN
represent a novel method for vaccination against tumor
antigens. Likewise, lentivirus vectors modified with Sindbis
virus envelope proteins, when linked to OVA, are taken up
by murine bone marrow derived DCs and stimulate OT-I
and OT-II T cells, CTL in vivo and protects mice against the
challenge of OVA expressing tumor cells [95]. The binding
of the modified lentivirus vectors with Sindbis virus enve-
lope proteins to DC-SIGN is mannose dependent. Further
modification of the vector to include 1-deoxymannojirimycin
and to inhibit mannosidases (an enzyme that removes man-
nose structures during glycosylation) resulted in enhanced
antibody responses [96]. These studies demonstrate that
glycoconjugates could be designed to target DC-SIGN for
developing tumor vaccines. The use of glycans to target
DC-SIGN has advantages over anti-DC-SIGN monoclonal
antibodies, as they reduce the risk of side effects and their
generation relies purely in organic chemistry approaches.
However, a recent study demonstrated that receptor-specific
antibodies are more effective at inducing immune responses
than carbohydrates (glycans) for DC-targeted vaccination
strategies [97].
L-SIGN or DC-SIGNR. L-SIGN or DC-SIGNR (also known
as CD299, CD209L, and Clec4M) is a type-II transmem-
brane C-type lectin receptor homologous to DC-SIGN (77%
amino acid sequence homology), highly expressed on liver
sinusoidal cells, endothelial vascular cells, and in the lymph
nodes, but not on DCs, in contrast to DC-SIGN (Table 1
and Figure 1). Like DC-SIGN, L-SIGN has a high affinity
binding to ICAM-3, HIV, simian immunodeficiency virus,
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Ebola virus, hepatitis C virus and respiratory syncytial virus
[72, 73, 75]. L-SIGN also binds with HIV gp120-binding
protein and Man9GlcNAc2 oligosaccharide, and binding is
enhanced up to 25-fold with Man9GlcNAc2 di-saccharide
[98]. Antibodies against L-SIGN, are taken up by human liver
sinusoidal endothelial cells and a cross-reactive antibody to
L-SIGN/DC-SIGN conjugated to tetanus toxoid induced T-
cell responses against tetanus toxoid. Thus, targeting L-SIGN
shows promise for the development of targeted vaccines [99].
A further 8-mouse homologs to human DC-SIGN have
been documented: SIGN-related gene 1 (SIGN-R1), SIGN-R2,
SIGN-R3, SIGN-R4, SIGN-R5, SIGN-R6, SIGN-R7, SIGN-R8
[100].The carbohydrate specificity of SIGN-R1 (CD209b) and
SIGN-R3 is similar to DC-SIGN, in that they bind mannose-
and fucose-containing ligands and interact with Lewis blood
antigens; however, SIGN-R1 and SIGN-R3 also interact with
sialylated Lex, a ligand for selectins [101, 102]. SIGN-R1
also binds to zymosan, to the capsular polysaccharide of S.
pneumoniae, and with low affinity to dextran and is highly
expressed by macrophages [101, 103–105]. Bovine serum
antigen (BSA) consisting, 51 mannoside residues (Man(51)-
BSA) binds to SIGN-R1 on lamina propria DCs in the
gastrointestinal tract and induces IL-10 cytokine secretion
by DCs, but not IL-6 and IL-12p70 [106]. In vitro and in
vivo, Man(51)-BSA stimulates CD4+ type 1 regulatory T-like
cells (Tr-1) but not CD4+CD25+Foxp3+ regulatory T cells,
suggesting that SIGN-R1 induces tolerance to antigens [106].
LSECtin. LSECtin (liver and lymph node sinusoidal endothe-
lial cell C-type lectin, Clec4G) is a type-II transmembrane C-
type lectin protein, similar to the related proteins DC-SIGN
and L-SIGN and is expressed in liver, lymph node cells, and
sinusoidal endothelial cells but not monocyte derived DCs
(Table 1). LSECtin binds to N-acetyl-glucosamine and fucose
but does not bind to galactose and may function in vivo as a
lectin receptor [107]. LSECtin is coexpressedwithDC-SIGNR
and CD23 and binds to ebola virus, filovirus glycoproteins,
lymphocytic choriomeningitis virus, and, to the S-protein of
SARS coronavirus but does not interact with HIV-1 and
hepatitis C [108]; although a study suggested that LSECtin
binds to hepatitis C virus, the interaction was in association
DC-SIGNR with [109]. Ligands binding to LSECtin are not
inhibited by mannan but by EDTA suggesting that the
LSECtin does not bind to mannose [108]. Recently, LSECtin
was shown to bindwith CD44 [110]. Another study, regarding
the expression of LSECtin demonstrated LSECtin, to be
expressed on human peripheral blood, thymic DCs, mon-
ocyte-derived macrophages and DCs [111], and to human
Kupffer cells [112]. Antibody or ligand-mediated engagement
of LSECtin activates rapid internalization of LSECtin [111]
indicating that LSECtin may be a suitable receptor for
targeting antigens in the development of vaccination regimes.
Furtherwork is required to determine the viability of LSECtin
to be an appropriate target for immunotherapy studies.
CIRE. CIRE (C-type lectin immune receptor, CD209) is a
murine type 2membrane proteinwhich belongs to theC-type
lectin receptors and is preferentially expressed by immature
CD8− splenic DCs (CD8−CD4+ and CD8−CD4−), on some
CD4+ DCs, and on plasmacytoid pre-DCs, with no expres-
sion on CD8+ DCs, macrophages, or monocytes (Table 1 and
Figure 1) [113]. CIRE that has 57% identity with DC-SIGN
is the murine homolog to human DC-SIGN and both bind
mannose residues [114]. However, CIRE is downregulated
after activation, and incubation with cytokines IL-4 and iL-13
does not enhance expression of CIRE, even though DC-
SIGN is enhanced, suggesting differences in gene regulation
between the two receptors [113]. CIRE consists of 238 amino
acids, and its extracellular domain contains a C-type lectin
domain; it is the ligand for ICAM-3 and is a receptor for HIV
binding facilitating trans-infection of T cells. Importantly,
CIRE does not bind with ebola virus glycoprotein, Leish-
mania mexicana, cytomegalovirus, and lentivirus, which are
defined ligands for DC-SIGN [113]. The lack of interaction is
due to defect in multimerization of CIRE which is thought
to be necessary for pathogen recognition by DC-SIGN [115],
suggesting that CIRE and DC-SIGN have functional differ-
ences.
Polyanhydride nanoparticles covalently linked to d-man-
nose and lactose increased the cell surface expression of
CD40, CD86, MHC class II, CIRE, and MR on bone marrow
derived DCs, compared to nonmodified nanoparticles,
although both nanoparticles were similarly internalized [116].
In addition, polyanhydride nanoparticles linked to galactose
and d-mannose, increased the cell surface expression (CD40,
CD86, MHC class I and II, CIRE, MR and macrphage galac-
tose lectin) and proinflammatory cytokines (IL-1beta, IL-6,
and TNF-alpha) on alveolar macrophages [117]. Likewise,
polyanhydride microparticles linked to (1,6-bis(pcarbox-
yphenoxy)hexane (CPH) and sebacic acid) or (1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane and CPH) were rapidly
phagocytosed within 2 hours by bone marrow derived DCs
and increased cell surface expression of CD40, CD86, MHC
class II and CIRE, and cytokines IL-12p40 and IL-6 [118].
Conjugation of the microparticles to OVA stimulated CD8+
OT-I and CD4+ OT-II T cells [118]. Blocking MR and CIRE
inhibited the upregulation of cell surface molecules on DCs,
suggesting that CIRE and MR engage together for DC
activation [116]. CIRE shows promise as an appropriate target
for antigen delivery for improved vaccine development.
2.2.2. Langerin. Langerin (CD207, Clec4K) is a type-II trans-
membrane cell surface receptor highly expressed on Langer-
hans cells, CD103+ DCs, and splenic CD8+ DCs (Table 1).
Langerin is a C-type lectin which highly binds to mannose
residues which are internalized by DCs into Birbeck granules
(where Langerin is localized) where there is access to the non-
classical antigen processing and presentation pathway.
A comparative study between murine DC-SIGN, SIGN-
R1, SIGN-R3, and Langerin demonstrated functional differ-
ences amongst the different C-type lectins, despite similari-
ties in the carbohydrate recognition domains. Murine DC-
SIGN did not bind dextran, OVA, zymosan, or heat-killed
Candida albicans, but SIGN-R1, SIGN-R3, and Langerin
showed distinct carbohydrate recognition [119]. Only SIGN-
R1 bound to Escherichia coli and Salmonella typhimurium
(Gram-negative bacteria), and neither murine DC-SIGN,
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SIGN-R1, SIGN-R3 nor Langerin bound to Staphylococcus
aureus (Gram-positive bacteria) [119]. In addition, SIGN-
R1 (but not the other lectin receptors) distinctively bound
to zymosan [119]. Langerhans cells (a subset of DCs) are
divided into two groups: (i) Langerhans cells that express
Langerin and (ii) epidermal Langerhans cells that go to lymph
nodes, which function and develop independently [120].
Anti-Langerin monoclonal antibody targeted to Langerin
was efficiently endocytozed by Langerhans cells in vitro [121]
and in vivo [122], suggesting further studies in immuniza-
tions through the skin for DC-based vaccination therapies.
Indeed, anti-Langerin monoclonal antibody conjugated to
HIV gag-p24 induced Th1 and CD8+ T-cell responses in
mice [123]. Interestingly, anti-DEC-205monoclonal antibody
was recently shown to be taken up by Langerin-positive DCs
[124], suggesting there is cross-talk between DEC-205 and
Langerin receptors. Further, a noncovalent fusion between
anti-Langerin monoclonal antibody and HA1 influenza
hemagglutinin elicited antigen-specific T-cell and antibody
responses in vitro and in vivo [125].
2.2.3. MGL. MGL (human macrophage galactose- and N-
acetylgalactosamine-specific C-type lectin) is the classi-
cal asialoglycoprotein receptor (Figure 1). MGL is highly
expressed on macrophages and immature DCs, whose ligand
specificity differs from DC-SIGN and L-SIGN, in that it
binds to galactose and N-acetylgalactosamine leading to
Th2 skewed immunity [126, 127]. In addition, MGL binds
the strongest to serine, threonine O-linked glycosylated Tn
antigen, a well-known human carcinoma-associated epitope,
and not to sialylated Tn antigen [128, 129]. Moreover, hMGL
binds to the group of filoviruses and to gonorrhea (via
lipooligosaccharides) leading to altered DC cytokine secre-
tion profiles and stimulation of CD4+Th responses (Table 1)
[77, 126, 127].
MUC1 peptide (3 tandem repeats, 60 amino acids enzy-
matically glycosylated with GalNAc) or short MUC1 or
MUC2 peptides containing Tn bound to immature DCs and
the MUC1-Tn glycopeptide localized within the MHC class I
and class II compartments [130]. MUC1 glycopeptides linked
to anti-MGL antibody led to upregulation of human DC cell
surface molecules and enhanced CD8+ T stimulation in
vitro [131]. In mice, MGL+ CD103- dermal DCs bound to
glycosylated Tn antigen in vivo, stimulating MHC class II
CD4+ T-cell responses. Intradermal immunization with Tn-
glycopeptides generates antibodies and Th2 cytokine secre-
tion by CD4+ T cells [132]. Recently, a mimic of galac-
tose/N-acetylgalactosamine stimulated bloodmonocytes and
myeloid derived DCs [133], suggesting that glycosylated
mimetics could be used to target antigens toMGL expressing
DCs. These results demonstrate that the targeting of MGL
receptor expressed on murine and human DCs stimulates T-
cell and antibody responses, and this approach could be used
to design novel anticancer vaccines.
2.2.4. Dectin-1 Subfamily. Dectin-1 (dendritic cell-associated
C-type lectin-1, DCAL-1, Clec7A) or beta-glucan receptor is a
C-type lectin receptor which is part of the NK gene complex
in the Dectin-1 cluster (Table 1 and Figure 1) [134]. It was
originally characterized to be DC specific (hence its name),
but it is now known to be also expressed on myeloid DCs,
CD8−CD4− DCs, dermal DCs, monocytes, macrophages,
neutrophils, microglia, T-cell subsets, B cells, mast cells,
eosinophils, and monocytes [134–136]. Dectin-1 is a receptor
for beta-glucan recognizing beta1,3 and beta1,6-linked glu-
cans on yeast, mycobacterial, and plant cell walls and plays
a role in innate immune responses [137, 138]. Zymosan, a
beta-glucan and mannan-rich ligand binds to Dectin-1 [139],
and Dectin-1 interacts with the tetraspanin molecule CD37.
Dectin-1 binds to Saccharomyces, Candida, Pneumocystis,
Coccidiodes, Penicillium, and Aspergillus, but not Cryptococ-
cus fungal species, leading to activation of Dectin-1+ cells and
elimination of fungal pathogens by activating inflammatory
responses, such as TNF-alpha, CDCL1, IL-1beta, GM-CSF,
and IL-6, by the presence of an ITAM in its cytoplasmic tail
[135]. In fact, Dectin-1 knockout mice are highly susceptible
to pathogenic infections due to inflammatory defects and
reduced fungal killing [140]. Furthermore, Dectin-1 binds to
bacteria resulting in TNF-alpha, IL-6, RANTES, G-CSF, and
IL-12 secretion [141]. The stimulation of inflammatory and
Th1 cytokines leads to the proposal of Dectin-1 targeting of
soluble antigens by appropriate ligands to stimulate cellular
immunity.
Anti-Dectin-1 and anti-Dectin-2 monoclonal antibodies
conjugated to OVA [142, 143] and induced significant expan-
sion of T cells in the draining lymph nodes of mice and IFN-
gamma secretion by T cells [142, 143]. Purified beta1,3-d-
glucan from Saccharomyces cerevisiae cell wall, free from
mannan and other proteins, binds to Dectin-1 receptor on
DCs. Beta1,3-d-glucan conjugated toOVAmatures bonemar-
row derived DCs was rapidly phagocytosed and stimulated
>100-fold more efficiently CD8+ OT-I and CD4+ OT-II T
cells, compared to OVA alone [144]. Immunization of mice
with beta1,3-d-glucan stimulated IgG2c antibodies, CD4+
T cells, IFN-gamma, and Th17 biased responses [144].
Thus, robust stimulation of humoral and cellular immune
responses results following immunization with vaccine can-
didates that target Dectin-1 receptor.
DNGR-1. DNGR-1 (NK lectin group receptor-1, Clec9A) is a
group V C-type lectin-like type II membrane protein located
close to Dectin-1 encoded within the NK gene complex.
DNGR-1 is expressed on murine CD8+ DCs not on CD4+
DCs, on CD11c+ DCs but not by CD11c− cells (B cells, T
cells, NK cells, NKT cells, macrophages, and granulocytes),
on plasmacytoid DCs, and on a small subset of human blood
DCs (BDCA-3+ DCs) and monocytes (CD14+CD16−) and
induces proinflammatory cytokines [145, 146]. DNGR-1 is
also not expressed by interstitial DCs, in skin epidermis,
and on GM-CSF derived bone marrow DCs but highly
expressed on Flt3 ligand bone marrow derived CD8+ DCs
(CD11blowCD24hiB220−) [146]. Anti-DNGR-1 monoclonal
antibody covalently conjugated to CD8+ peptide from OVA,
induced OT-I CD8+ T-cell proliferation and IFN-gamma
secretion in vivo, and only CD8+ DCs and not plasmacytoid
DCswere involved in the presentation of the peptide toCD8+
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T cells [146]. In the presence of anti-CD40, CTLs are primed
in vivo and preventOVA+ expressing tumor cell growth [146].
Injection of anti-DNGR-1 monoclonal antibody-OVA con-
jugate into mice was endocytozed by CD8+ DCs, presented
antigen to CD4+ T cells, and played amajor role in the differ-
entiation of CD4+T cells into Foxp3+ regulatory T cells [147].
The addition of the adjuvant poly I:C enhanced IL-12 medi-
ated immunity, whereas the adjuvant curdlan primed Th17
cells [147]. In addition, vaccinia virus infected dying cells are
endocytozed by DNGR-1 on DCs and mediate cross-priming
of antivaccinia virus infected cell CD8+ T-cell responses; loss
of DNGR-1 impairs CD8+ CTL responses [148, 149]. Thus,
DNGR-1 regulates cross-presentation of viral antigens and
could be further assessed as a target for vaccination protocols.
Furthermore, a single injection of anti-Clec9A monoclonal
antibody induced striking antibody and CD4+ T cells re-
sponses in the absence of adjuvant or danger signals in mice
and in TLR knockout mice [150, 151]. Targeting antigens
to Clec9A shows promise to enhance vaccine efficiency;
indeed, anti-Clec9Amonoclonal antibody conjugated toHIV
gag-p24 induced strong Th1 and CD8+ T-cell responses in
mice [123]. DNGR-1/Clec9A could prove useful for develop-
ing immunotherapy protocols for cancer and other diseases.
MICL. MICL (myeloid inhibitory C-type lectin-like receptor,
Clec12A) is homologous toDectin-1 and is part of theDectin-
1 cluster [152].Numerous other groups identified this receptor
and named it C-type lectin-like molecule-1 (CLL-1), DC as-
sociatedC-type lectin 2 (DCAL-2), and killer cell lectin-like
receptor 1 (KLRL1) [153–155]. MICL is expressed on granu-
locytes, monocytes, macrophages, B cells, CD8+ T cells in
peripheral blood, and DCs (Table 1) [156], and, contains a
tyrosine based inhibitory motif in its cytoplasmic tail, similar
to lectin-like receptor for oxidized density lipoprotein-1
(LOX-1) and Dectin-1, and can inhibit cellular activation.
Hence, MICL is a negative regulator of granulocytes and
monocytes [152].MICLhas a range of functions including cell
adhesion, cell-cell signaling, turnover of glycoproteins, and in
inflammation and in immune responses.
CLEC2. CLEC2 (also known as Clec1B), a C-type lectin-like
receptor 2, is expressed on NK cells, DCs, monocytes,
granulocytes, platelets, megakaryocytes, and liver sinusoidal
endothelial cells (Table 1) [157]. CLEC2 is a platelet activation
receptor for the endogenous ligand, podoplanin (a mucin-
like sialoglycoprotein) expressed on a number of cells includ-
ing lymphatic endothelial cells and implicated in cancer cell
metastasis [158]. CLEC2 on platelets binds to HIV-1 and
facilitates HIV-1 spread to other immune cells. The binding
of HIV-1 to platelets via CLEC2 is highly dependent on DC-
SIGN, suggesting that the two coexist [159]. In addition,
the snake venom rhodocytin binds to CLEC2 on platelets
and activates cell signaling [160]. Not much is known about
CLEC2 and stimulation of immune responses, but its expres-
sion on DCs and its colocalization with DC-SIGN suggest it
may have immune stimulatory effects.
CLEC12B. CLEC12B (macrophage antigen H) is part of the
NK gene complex/Dectin-1 cluster of C-type lectin receptors,
highly expressed on macrophages, monocytes, and DCs and
contains immunoinhibitory sequences in its cytoplasmic tail
[161, 162]. There not much known regarding CLEC12B and
its function on DCs and macrophages. It is possible that
CLEC12B could be used as a receptor to target antigens
for immunotherapy studies for diseases, including cancer;
however, this is still to be determined.
LOX-1. LOX-1 (lectin-like receptor for oxidized density lipo-
protein-1, Clec8A) is part of the Dectin-1 cluster of C-type
lectin receptors. LOX-1 is also considered to be a member of
the scavenger receptor family. LOX-1 is expressed on endo-
thelial cells, smooth muscle cells, platelets, fibroblasts, and
macrophages and binds to Gram-positive and gram-negative
bacteria, oxidized-LDL modified lipoproteins, phospho-
lipids, apoptotic cells, C-reactive protein, and heat shock pro-
tein (HSP)-70 [163]. LOX-1 does not contain the classical sig-
nalingmotifs in its cytoplasmic tail but is involved in endocy-
tosis, phagocytosis, cytokine production, and in the produc-
tion of reactive oxygen species [164, 165]. As a consequence
of the binding of LOX-1 to HSP-70, DC-mediated antigen
cross-presentation results [166]. An anti-LOX-1 monoclonal
antibody which inhibits the binding of HSP-70 to DCs
also inhibits HSP-70 induced cross-presentation of antigens.
Anti-LOX-1 monoclonal antibody linked to OVA protein
specifically stimulated CD4+ OVA T-cell hybridoma in vitro
as measured by IL-2 production [166]. Injection of anti-LOX-
1-OVA conjugated into mice prevented the growth of OVA
expressing tumor cells [166]. Hence, targeting LOX-1 is a
promising target for cancer immunotherapy studies.
2.2.5. DC Immunoreceptor (DCIR) Subfamily
DCIR. DCIR (DC immunoreceptor) is a C-type lectin re-
ceptor, with tyrosine based immune-inhibitory functions,
Clec4A). DCIR is primarily expressed on plasmacytoid DCs
(pDCs), on immature andmaturemonocyte-derivedDCs, on
monocytes, macrophages, and B cells, and aftermaturation of
pDCs, DCIR is reduced (Table 1). Binding to TLR9 on pDCs
induces IFN-alpha, which is inhibited by DCIR activations
whilst costimulatory molecules are not affected [167]. DCIR
has a range of functions including cell adhesion, cell-cell
signaling, turnover of glycoproteins, and in inflammation and
in immune responses. Targeting DCIR is rapidly internalized
into clathrin pits and processed and presented to T cells [167].
An anti-DCIRmonoclonal antibody is rapidly internalized by
human monocyte derived DCs into endolysosomal vesicles
and does not unregulate TLR4 nor TLR8 mediated upreg-
ulation of costimulatory molecules, CD80 and CD86, but
does inhibit TLR8mediated IL-12 and TNF-alpha production
[168]. Thus, targeting DCIR activates T cells but also inhibits
TLR8-induced (IL-12 and TNF-alpha production) and TLR9-
induced (IFN-alpha production), which may be applied in
vaccine development for disease prevention and treatment.
Targeting antigens to DCIR were evaluated for their potential
to stimulate CD8+ T-cell responses. Anti-DCIR monoclonal
antibody linked to influenza matrix protein, melanoma anti-
genMART-1, or to HIV gag antigens resulted in expansion of
CD8+ T cells in vitro [169] and stimulation of Th1 and
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CD8+ T cells in vivo [123]. The addition of TLR-7/8 agonists
enhanced T expansion of primed CD8+ T cells and induced
the production of IFN-gamma and TNF-alpha and reduced
the levels of Th2 cytokines [169]. It is clear that, antigen tar-
geting via the DCIR activates specific CD8+ T-cell immune
responses.
Dectin-2. Dectin-2 (or DCAL-2, Clec6A) or beta-glucan re-
ceptor is a C-type lectin receptor expressed on DCs, macro-
phages, neutrophils, and monocytes (Table 1) [170]. Dectin-2
is a receptor for beta-glucan recognizing beta1,3 and beta1,6-
linked glucans on yeast, mycobacterial, and plant cell walls
and plays a role in innate immune responses [137, 138]. Anti-
Dectin-2 monoclonal antibody conjugated to antigen stim-
ulate, CD8+ T cells in mice [142]. In addition, a lentivector
using the mouse Dectin-2 gene promoter, was taken up by
bonemarrowderivedDCs, Langerhans cells, anddermalDCs
in vitro [171]. The Dectin-2 lentivector encoding the human
melanoma antigen, NY-ESO-1, stimulated CD4+ and CD8+
T cells in mice [171]. Thus, Dectin-2 expressed on DCs is a
potential targeting protein for vaccinations.
BDCA-2. Blood DC antigen 2 (BDCA-2, Clec4C) is a type II
C-type lectin expressed on human bloodDCs, which has 57%
homology with its murine homolog Dectin-2. Anti-BDCA-2
monoclonal antibody is rapidly internalized by plasmacytoid
DCs and presented to T cells and suppresses the induction of
IFN-alpha/beta cytokine secretion [172].
3. DEC205
DEC-205 (CD205 or lymphocyte antigen Ly 75) is a type-I
integral membrane protein homologous to the macrophage
MR family of C-type lectins, which binds carbohydrates and
mediates endocytosis (Figure 1) [173]. DEC-205 is primar-
ily expressed on DCs and thymic epithelial cells. DEC205
mediates a number of different biological functions, such
as binding and internalization of ligands for processing and
presentation by DCs (Table 2). Although the ligands which
bind toDEC205 are not clear, following ligand binding, DEC-
205 is rapidly internalized bymeans of coated pits and vesicles
and is delivered to multivesicular endosomal compartments
that resemble the MHC class II-containing vesicles impli-
cated in antigen presentation.Due to the endocytic properties
of DEC205, it is a promising receptor for antigen delivery
for vaccines and targeted immunotherapies [174]. Upon DC
maturation, DEC205 is upregulated, unlike othermembers of
the macrophage MR family.
In an attempt to design vaccines that target DEC205, the
cytosolic tail of DEC-205 was fused to the external domain
of the CD16 Fc gamma receptor and was studied in stable
L cell transfectants [175]. The DEC-205 tail recycled CD16
throughMHC II-positive late endosomal/lysosomal vacuoles
and also mediated a 100-fold increase in antigen presentation
to CD4+ T cells. An anti-DEC-205 monoclonal antibody
conjugated to OVA was shown to stimulate OVA-specific
CD4+ and CD8+ T cells by CD11+ lymph node DCs, but
not by CD11c− DCs [176]. Injection of anti-DEC-205-OVA
conjugate in mice was taken up by draining lymph node DCs
and stimulated CD8+ T (OT-I) cells 400 times more effi-
ciently compared to OVA alone; this response was further
enhanced in vivo (as measured by IL-2, IFN-gamma, CTL,
and tumor protection), with the addition of anti-CD40
antibody (a DC maturation stimulus) [176]. Further, anti-
DEC-205 antibody-OVA intradermally injected in mice was
rapidly taken up by Langerhans cells and stimulated both
CD4+ and CD8+ T-cell responses [122]. Langerin positive
skin DCs play a major role in transport of anti-DEC-205-
OVA complex, although Langerin negative dermal DCs and
CD8+ DCs were responsible for the T-cell stimulation [124].
Hence, there is cross-talk between DC subsets.
Conjugation of the anti-DEC-205 monoclonal antibody
to the melanoma antigen tyrosinase-related protein TRP-2,
induced CD4+ and CD8+ T-cell responses which protected
mice against B16 tumor cell growth and slowed growth
of established B16 tumors [177]. In addition, anti-DEC205
monoclonal antibody linked to survivin (a survival pro-
tein overexpressed on carcinoma cells) together with anti-
CD40 and poly I:C stimulated surviving-specific CD4+T-cell
responses (IFN-gamma, TNF-alpha, IL-2 secretion), lytic
MHC class II+ T cells but not CD8+ T cells. Depletion
of CD25+foxp3+ cell prior to immunization led to further
enhanced immune responses [178]. Interestingly, HER2/neu
protein expressed on breast cancer cells was genetically
engineered into anti-DEC205 monoclonal antibody, and in
combinationwith poly I:C andCD40 antibody, elicited robust
CD4+ and CD8+ T-cell responses and antibody responses
which protected mice against Her2+ breast tumor challenge
[179]. Further, HIV p24 gag protein conjugated to anti-
DEC205 monoclonal antibody, or HIV gag p24-single chain
DEC-205 Fv DNA vaccines, was taken up by DCs and stimu-
lated proliferation and IFN-gamma secretion byCD8+T cells
that had been isolated from HIV-infected donors [180, 181].
Similarly, in mice, immunization led to Th1 (IFN-gamma,
IL-2), CD4+ and CD8+ T-cell responses, and 10-fold higher
antibody levels [123, 181–183]. Likewise, priming with the
DNA vaccine and boosting with adenoviral vector (compris-
ing anti-DEC205monoclonal antibody conjugated toOVAor
HIV-1 gag together with anti-CD40) induced strongCD8+T-
cell responses; no enhanced effect was seen with the addition
of TLR-9 ligand CpG and TLR-3 ligand poly I:C or CD40
ligand [184]. Recombinant Newcastle disease virus vaccine
vector (rNDV) on its own induces IFN-alpha and IFN-beta
production and DC maturation. Immunization with rNDV
encoding anti-DEC205 and HIV-1 gag antigen enhanced
CD8+ gag specific T-cell responses and increased the number
of CD4+ and CD8+ T cells in the spleen compared to
rNDV encoding gag antigen alone [185]. Furthermore, mice
were protected against challenge of recombinant vaccinia
virus expressing HIV gag protein [185]. Conjugation of
anti-NLDC-145 monoclonal antibody (monoclonal antibody
against murine DEC205) to a model antigen stimulated both
antibody and T-cell responses in animal models [186]. Con-
versely, using a self antigen, proteolipid protein (PLP
139−151
)
conjugated to anti-DEC205 monoclonal antibody tolerized
T cells in vivo and reduced the secretion of IL-17 by
CD4+ T cells and in vitro CD4+Vbeta6+ T-cell receptor T
cells specific for PLP
139−151
became anergic [187]. Hence,
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Table 2: Summary of dendritic cell receptors targeted for vaccine development: other receptors.
Receptor Designation Function
3. Type-1 integral membrane proteins
3.1. DEC205 CD205 Homologous to the mannose receptor.
Ly 75 Expressed on DCs and thymic epithelial cells. Targeting DEC205induces an array of immune responses.
4. Scavenger receptors
4.1. Scavenger receptor
Expressed on macrophages. Bind to modified low density lipoproteins
(LDL) by oxidation (oxLDL) or acetylation (acLDL). Bind to CD68,
macrosialin, mucins, and LOX-1. Targeting of scavenger receptors
induces immune responses in mice.
4.1.1. Scavenger receptor class A SR-A1 Expressed on macrophages as a trimer.
SR-A2
Members include SCARA1 (MSR1), SCARA2 (MARCO), SCARA3,
SCARA4 (COLEC12), and SCARA5.
4.1.2. Scavenger receptor class B SR-B1
Consists of 2 transmembrane units.
Members include SCARB1, SCARB2, and SCARB3 (CD36).
4.1.3. Scavenger receptor class C SR-B1
Consists of a transmembrane region in which the N-terminus is
located extracellularly.
4.2. DC-asialoglycoprotein receptor
(DC-ASGPR)
A lectin-like scavenger receptor. Expressed on monocyte derived DCs
(CD14+CD34+), tonsillar interstitial-type DCs, and granulocytes.
Targeting DC-ASGPR induces suppressive responses.
5. F4/80 receptor
Expression restricted to macrophages. Murine homolog of the
epidermal growth factor-like module containing mucin-like hormone
receptor-1 protein encoded by the EMR1 gene.
5.1. FIRE
Expressed on CD8−CD4+ and CD8−CD4− immature DCs, and
weakly on monocytes and macrophages. Targeting FIRE stimulates
immune responses in mice.
6. DC-specific transmembrane protein
(DC-STAMP)
Expressed on DCs and activated blood DCs.
Targeting DC-STAMP results in immunosuppressive responses in
some studies and in other studies stimulates strong cellular responses.
7. FcR
Links humoral and cellular immune (Fc Receptor) responses, links
innate and adaptive immune responses by binding pathogens and
immune complexes, and stimulates T cells. Targeting FcR is a novel
vaccine strategy for stimulating immune responses.
targeting self-antigens to DEC-205 induces tolerance. It
is clear that, targetingDCs usingDEC-205 directed antibody-
antigen conjugates represents a novel method of inducing
tolerance to self-antigens and antitumor immunity in vivo.
4. Scavenger Receptor
The scavenger receptors (SRs) are a group of receptors that
recognize modified low density lipoprotein (LDL) by oxida-
tion (oxLDL) or acetylation (acLDL) (Figure 1). Scavenger
receptor was given its name based on its “scavenging” func-
tion. SR is primarily present on macrophages internalize
endotoxins, oxLDL, and other negatively charged proteins.
SR, are grouped into classes A, B, and C according to their
structural features. (i) Scavenger receptor class A (SR-A1,
SR-A2) is mainly expressed on macrophages as a trimer
and has 6 domains (cytosol, transmembrane, spacer, alpha-
helical coiled-coil, collagen-like, and cystein-rich domains)
(Table 2). Members include SCARA1 (MSR1), SCARA2
(MARCO), SCARA3, SCARA4 (COLEC12), and SCARA5.
(ii) Class B (SR-B1) has 2 transmembrane regions and are
identified as as ocLDL receptors. Members include SCARB1,
SCARB2, and SCARB3 (CD36). (iii) Class C has a transmem-
brane region in which the N-terminus is located extracellu-
larly. There are other receptors that have been reported to
bind to oxLDL which include CD68 and its murine homolog
macrosialin, mucins, and LOX-1.
Despite the scavenging functions of SR, SRs have been
shown to endocytoze antigens and present antigens to MHC
class I and II and stimulate effective CD4+ and CD8+ T-cell
responses. Using 200 nm particles coated with oligonu-
cleotide polyguanylic acid (SR-targeting agent) showed spe-
cific binding to SR, and particles were localized in intracellu-
lar vesicles and processing via the endocytotic pathway [188].
An early example demonstrating immune responses genera-
tion was with maleylated OVA which bound to SR, enhanc-
ing its presentation and stimulation of CTLs by macrophages
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and B cells [189]. Maleylated diphtheria toxoid was also more
immunogenic than nonmaleylated diphtheria toxoid, gener-
ating enhanced antibody and T-cell proliferative responses
[190]. Likewise, in chickens, immunization with maleylated
bovine serumalbumin yieldedTh1 immune response via anti-
bodies. In addition, high levels of IFN-gamma mRNA were
detected in splenocytes compared to nonmaleylated bovine
serum antigen that stimulated Th2 immune responses [191].
Tropomyosin from shrimp causes allergic responses in some
individuals inducing a dominantTh2 cytokine profile and IgE
antibody responses. Modifying tropomyosin to maleylated
tropomyosin, diverted responses from IL-4 Th2 dominant
proallergic phenotype to an IFN-gammaTh1 antiallergic phe-
notype. Thus, modification of proteins to target the SR
on macrophages elicits Th1 IFN-gamma responses [192].
SRs recognize malondialdehyde and acetaldehyde adducted
proteins [193] and when linked to hen egg lysozyme protein,
stable adducts (oxidative products) are formed. Immuniza-
tion inmice results in strong T-cell proliferative and antibody
responses [193]. MARCO, a SR class A family member ex-
pressed on murine macrophages and human monocyte-
derived DCs, plays an influential role in mediating immune
responses. Anti-MARCO antibody linked to tumor lysate-
pulsed DCs enhance, tumor-reactive IFN-gamma producing
T cells and reduced tumor growth in mice [194]. These
studies demonstrate the implications of targeting antigens to
MARCO and other SRs for use in human clinical DC vaccine
trials.
4.1. DC-ASGPR. DC-asialoglycoprotein receptor (DC-
ASGPR) is a lectin-like scavenger receptor. It is expressed on
monocyte derived DCs (CD14+CD34+), on tonsillar inter-
stitial-type DCs and granulocytes, but not on T cells, B cells,
NK cells, monocytes, Langerhans cells, and CD1a derived
DCs (Table 2) [195]. Anti-DC-ASGPR monoclonal antibody
is rapidly internalized into early endosomes, indicating that
DC-ASGPR is involved in antigen capture and processing
[195]. Targeting DC-ASGPR induces a suppressive CD4+
T-cell response that secretes IL-10 in vitro and in vivo [196].
Hence, targeting antigens to DC-ASGPR induces antigen
specific IL-10-producing suppressive T cells, and DC-ASGPR
could be utilized to induce a suppressive immunotherapeutic
effect to self- or non-self-antigens.
5. F4/80 Receptor
F4/80 is restricted to macrophages, and for over 40 years
F4/80 has been used to identify and characterize macro-
phages in tissues and its functional role in macrophage
biology [197]. F4/80 is the murine homolog of the epidermal
growth factor-like module containing mucin-like hormone
receptor-1 protein encoded by the EMR1 gene. F4/80 al-
though highly expressed onmacrophages does not play a role
inmacrophage development (Table 2 and Figure 1). However,
F4/80 receptor was found to be necessary for the induction of
CD8+ T regulatory cells responsible for peripheral immune
tolerance [197]. No ligands to F4/80 are known, and much
work is still required to understand the role of F4/80 in
the immune response and could be a novel antigen targeting
receptor.
5.1. FIRE. FIRE is an F4/80-like receptor expressed specif-
ically on CD8−CD4+ and CD8−CD4− immature DCs and
weakly on monocytes and macrophages (Table 2) [198].
Rat anti-FIRE (6F12) and rat anti-CIRE (5H10) antibodies
(targeting the FIRE and CIRE receptors on CD8− DCs)
were injected into mice, and anti-rat Ig titres were measured
and compared to control rat antibody [198]. Anti-FIRE and
anti-CIRE IgG1 antibody responses were 100–1,000-fold
greater to non-targeted control rat antibody. The magnitude
of the responses was equivalent to that seen when CpG
was included as an adjuvant [198]. Conversely targeting the
DEC205 receptor, expressed on CD8+ DCs with rat anti-
DEC-205 antibody (NLDC-145), did not induce humoral
immune responses unless CpG was added [198]. This study
demonstrated the differences in the ability of CD8+ and
CD8− DC subsets to stimulate immune responses in vivo.
6. DC-STAMP
DC-specific transmembrane protein (DC-STAMP) contains
7 transmembrane regions and has no sequence homology
with other multimembrane cell surface receptors and has an
intracellular C-terminus. DC-STAMP resides in the endo-
plasmic reticulum, where it interacts with LUMAN (also
known as CREB3 or LZIP) of immature DCs and upon
stimulation DC-STAMP translocates to the Golgi apparatus
and is expressed on the cell surface upon maturation [199].
DC-STAMP is specifically expressed by DC, on activated but
not resting blood DCs, and not in a panel of other leuko-
cytes or nonhematopoietic cells (Table 2) [200]. DC-STAMP
lentiviral vector-OVA in mice tolerize OT-I CD8+ and OT-II
CD4+ T-cell responses, leading to elimination and functional
inactivation of CD4 and CD8 T cells in peripheral organs and
in the thymus [201]. Binuclear and multinuclear DCs express
low levels of MHC class II and IL-12p70 with high levels
of IL-10 which suppress T-cell proliferative responses [202].
Blocking of DC-STAMP decreased the number of binuclear
cells, suggesting that the DC-STAMP is responsible for the
immunosuppresive effects of binucleated DCs [202]. Thus,
targeting antigens to DC-STAMP tolerize antigen specific T-
cell responses in vivo. Conversely, using DC-STAMP pro-
moter driven construct linked to OVA, resulted in strong
OVA-specific CD4+ and CD8+ T-cell responses in vitro and
in vivo and protected mice against OVA+ tumor challenge
[203].Thus, DC-STAMP shows promise as a target for cancer
vaccine antigen targeting approach.
7. Fc Receptor
Fc receptors (FcR) for immunoglobulins link humoral and
cellular immune responses [204]. They also link the innate
immune response to the adaptive immune response by bind-
ing to pathogens and immune complexes and stimulating T
cells. There is a different FcR for each class of immunoglob-
ulin Fc𝛼lphaR (IgA), Fc𝜀psilonR (IgE), Fc𝛾ammaR (IgG),
14 Journal of Drug Delivery
and Fc𝛼lpha/𝜇egaR (IgA and IgM). There are 4 types
of Fc𝛾ammaR: Fc𝛾ammaRI (CD64), Fc𝛾ammaRII (CD32),
Fc𝛾ammaRIII (CD16), and Fc𝛾ammaRIV. It is becoming
evident that antibody-antigen complexes present antigen
more efficiently than antigen alone via the Fc𝛾ammaR.
OVA antigen complexed with anti-OVA antibody injected
into mice is presented 10 times more efficiently to T cells
compared to OVA alone [205]. An interesting study dem-
onstrated that 𝛾amma-chain knockout mice which lack
Fc𝛾ammaRI/Fc𝛾ammaRIII/Fc𝛾ammaRIV induced similar
CD8+ T-cell responses in mice compared to the wild-type
mice. However, CD8+ T-cell proliferative responses were
reduced in Fc𝛾ammaRI/Fc𝛾ammaRII/Fc𝛾ammaRIII knock-
out mice compared to wild type mice, suggesting that all FcR
other than Fc𝛾ammaRIV take up immune complexes and
stimulate CD8+ T-cell responses [205]. In a comparative
study between FcR and MR targeting of prostate serum anti-
gen (PSA), PSA antigen/anti PSA antibody complex induced
both CD4+ and CD8+ T-cell responses however, mannose-
PSA stimulated only CD4+ T cells [206]. However, given that
the antigen is mannosylated in the appropriate form, CD8+ T
cells could be generated, as seen with oxidized versus reduced
mannan-MUC1 conjugates (Table 2) [6, 8, 12, 13, 21].
7.1. Fc𝛾ammaRIII (CD16). Fc𝛾ammaRIII is also known as
CD16. Conjugation of tetanus toxoid 14 amino acid peptide
or a hepatitis C virus peptide to anti-CD16 antibody activated
CD4+ T-cell clones 500 times more effectively compared to
peptide alone [207]. Hence, Fc𝛾ammaRIII has properties of
antigen uptake, processing, and presentation to T cells for
effective immune response generation.
7.2. Fc𝛼lphaRI (CD89). Fc𝛼lphaRI is expressed on myeloid
cells, interstitial-type DCs, CD34+ DCs, and monocyte
derived DCs [208]. Fc𝛼lphaR1 binds to Porphyromonas gin-
givalis, Bordetella pertussis, and Candida albicans stimulating
efficient immune responses for their elimination [209–213].
Cross-linking of Fc𝛼lphaRI induced internalization of recep-
tor and activation of DCs; however, there was very minimal
antigen presentation [214, 215]. Therefore, it is unlikely that
targeting antigen to human FcalphaRI will result in generat-
ing increased immune responses.
7.3. Fc𝜀psilonRII (CD23). Fc𝜀psilonRII (CD23) is a type 2
transmembrane C-type lectin that binds with low affinity
to IgE. CD23 also interacts with CD21, CD11b, and CD11c.
Unlike other Fc receptors, CD23 is a C-type lectin. Its main
function is in allergic responses, and it is expressed on acti-
vated B cells, activated macrophages, eosinophils, platelets,
and follicular DCs. CD23 is noncovalently associated with
DC-SIGN and MHC class II on the surface of human B
cells. Following endocytosis of anti-CD23 antibodies, CD23
is lost from the cells; however, endocytosis anti-MHC class II
antibody leads to recycling of HLA-DR-CD23 complex to the
cell surface, consistent with the recycling of MHC class II in
antigen presentation; CD23 is internalized into cytoplasmic
organelles that resembled the compartments for peptide
loading (MHCclass II vesicles) [216].Thismay lead to peptide
presentation, and the return of CD23 with MHC class II to
the cell surface may aid in the stabilization of B-cell-T-cell
interactions, leading to T-cell responses [216]. It is apparent
that human andmurineB cells take up IgE-antigen complexes
via CD23 and present antigenic peptides via MHC class
II stimulating CD4+ T cells. TNP-(trinitrophenyl-) specific
IgE linked to BSA or OVA and injected into mice results in
100-fold enhanced IgG antibody responses as compared to
either IgE or BSA or OVA injected alone; the enhanced anti-
body effects are completely dependent on CD23 [217, 218]. In
addition, the coexpression of CD23 with DC-SIGN further
suggests that antigen presentation and stimulation of antigens
is possible between the cross-talk of these two receptors.
Hence, targeting CD23 is a novel vaccine strategy for stim-
ulating CD4+ T-cell immune responses.
8. Conclusions
A promising strategy to improve the immunogenicity of
antigens is “antigen targeting.” DCs are unique in their ability
to present antigen to naiveT cells and, hence, play amajor role
in initiating immune responses. Characterization of DC re-
ceptors aid in the understanding of the mechanism underly-
ing their potent antigen presenting capacity. A major chal-
lenge for vaccine design is targeting antigens to DCs in vivo,
facilitating cross-presentation, and conditioning the mi-
croenvironment for Th1- and Th2-type immune responses.
We have analysed numerous DC cell surface receptors, which
function in inducing cellular responses and individually each
shows promise as targets for vaccine design against cancer.
More recently there has been an upsurge of information
regarding toll-like receptor (TLR) targeting and stimulation
of DCs via TLR. It is clear that in mice, use of TLR ligands to
activate DCs stimulates effective cellular immune responses
and activation ofDCs.However, no substantial TLR-targeting
vaccine trials have been completed in humans and it remains
to be determined whether TLR targeted approach will result
in significant benefits in humans as those seen in mice.
Furthermore, targeting antigens to chemokine receptors [1]
on DCs (CCR1, CCR2, CXCR4, CCR5, CCR6, and CXCR1)
generates enhanced immune responses in vitro and in vivo.
Furthermore, bacterial toxins, DC binding peptides and
internalization peptide (Int) also target antigens to DCs;
however, the targeting does not involve receptor targeting. It
is clear that receptor targeting of antigens is a promising new
approach for cancer immunotherapy studies.
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